Official_Bellicum_Logo_RGB.jpg
Bellicum Announces Interim BPX-601 Data and Corporate Restructuring
October 29, 2020 17:15 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced interim data...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2020 16:07 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Official_Bellicum_Logo_RGB.jpg
Bellicum to Participate in Two Upcoming Virtual Conferences
September 28, 2020 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Second Quarter 2020 Financial Results and Provides Operational Update
August 06, 2020 16:05 ET | Bellicum Pharmaceuticals, Inc.
Received FDA IND clearance to initiate Phase 1/2 clinical trial for BPX-603 for HER2+ solid tumors Initial data for BPX-601 cohort 5C to be presented at a medical meeting by the end of 2020 ...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2020 16:08 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, July 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Official_Bellicum_Logo_RGB.jpg
Bellicum to Report Second Quarter 2020 Financial Results and Provide Corporate Update
July 30, 2020 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports First Quarter 2020 Financial Results and Provides Operational Update  
May 07, 2020 16:05 ET | Bellicum Pharmaceuticals, Inc.
Bellicum’s three GoCAR™ programs remain on track Completed $15 million sale of manufacturing, office and laboratory facility to MD Anderson and entered into supply agreement HOUSTON, May 07, 2020 ...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 30, 2020 16:09 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, April 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Official_Bellicum_Logo_RGB.jpg
Bellicum Completes Sale of Houston Facility
April 15, 2020 07:30 ET | Bellicum Pharmaceuticals, Inc.
Purchase price of $15 million from sale of manufacturing, office and laboratory facility Current and future GoCAR™ product candidates to be manufactured by MD Anderson HOUSTON, April 15, 2020 ...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Operational Update
March 12, 2020 16:05 ET | Bellicum Pharmaceuticals, Inc.
Presented new Phase 1 translational results for BPX-601 at ASCO GI Initiated new GoCAR-NK™ program targeting BCMA Entered into asset purchase agreement and licensed technology to MD Anderson ...